MA43288A1 - Procédés de production et formes cristallines d'un inhibiteur mdm2 - Google Patents
Procédés de production et formes cristallines d'un inhibiteur mdm2Info
- Publication number
- MA43288A1 MA43288A1 MA43288A MA43288A MA43288A1 MA 43288 A1 MA43288 A1 MA 43288A1 MA 43288 A MA43288 A MA 43288A MA 43288 A MA43288 A MA 43288A MA 43288 A1 MA43288 A1 MA 43288A1
- Authority
- MA
- Morocco
- Prior art keywords
- production processes
- crystal forms
- mdm2 inhibitor
- intermediates
- chlorophenyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940083338 MDM2 inhibitor Drugs 0.000 title 1
- 239000012819 MDM2-Inhibitor Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 isopropylsulfonyl Chemical group 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Epoxy Compounds (AREA)
Abstract
La présente invention concerne des procédés de production d'acide 2-((3r,5r,6s)-5-(3- chlorophényl)-6- (4-chlorophényl)-l-((s)-l-(isopropylsulfonyl)-3-méthylbutan-2-yl)-3- méthyl-2-oxopipéridin-3-yl)acétique ainsi que des intermédiaires et des procédés de production des intermédiaires. L'invention concerne également des formes cristallines du composé et les intermédiaires.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361833196P | 2013-06-10 | 2013-06-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA43288A1 true MA43288A1 (fr) | 2020-04-30 |
MA43288B1 MA43288B1 (fr) | 2020-10-28 |
Family
ID=51063849
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53572A MA53572A1 (fr) | 2013-06-10 | 2014-06-09 | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
MA38714A MA38714A1 (fr) | 2013-06-10 | 2014-06-09 | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
MA43288A MA43288B1 (fr) | 2013-06-10 | 2015-12-23 | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53572A MA53572A1 (fr) | 2013-06-10 | 2014-06-09 | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
MA38714A MA38714A1 (fr) | 2013-06-10 | 2014-06-09 | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
Country Status (37)
Country | Link |
---|---|
US (10) | US9376386B2 (fr) |
EP (2) | EP3008039B1 (fr) |
JP (4) | JP6998655B2 (fr) |
KR (3) | KR20210121270A (fr) |
CN (3) | CN110627708A (fr) |
AP (1) | AP2015008891A0 (fr) |
AR (2) | AR096582A1 (fr) |
AU (5) | AU2014278428B2 (fr) |
BR (2) | BR122020003153B1 (fr) |
CA (4) | CA3201958A1 (fr) |
CL (3) | CL2015003589A1 (fr) |
CR (2) | CR20210290A (fr) |
CY (1) | CY1123661T1 (fr) |
DK (1) | DK3008039T3 (fr) |
EA (3) | EA201891642A1 (fr) |
ES (1) | ES2851023T3 (fr) |
HR (1) | HRP20202065T1 (fr) |
HU (1) | HUE053047T2 (fr) |
IL (4) | IL297860A (fr) |
JO (2) | JOP20200296A1 (fr) |
LT (1) | LT3008039T (fr) |
MA (3) | MA53572A1 (fr) |
MX (2) | MX2015016856A (fr) |
MY (1) | MY194848A (fr) |
NZ (1) | NZ714821A (fr) |
PE (2) | PE20160113A1 (fr) |
PH (1) | PH12015502705A1 (fr) |
PL (1) | PL3008039T3 (fr) |
PT (1) | PT3008039T (fr) |
RS (1) | RS61192B1 (fr) |
SG (2) | SG10201801402XA (fr) |
SI (1) | SI3008039T1 (fr) |
TN (1) | TN2015000521A1 (fr) |
TW (3) | TWI698428B (fr) |
UA (1) | UA121301C2 (fr) |
UY (1) | UY35605A (fr) |
WO (1) | WO2014200937A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
WO2013049250A1 (fr) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
WO2014151863A1 (fr) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Composés morpholinone d'acide hétéroaryle utilisés comme inhibiteurs de mdm2 pour le traitement du cancer |
JOP20200296A1 (ar) * | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
MX2020013670A (es) | 2013-11-11 | 2022-09-30 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. |
EP3458101B1 (fr) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Conjugués anticorps-protac et procédés d'utilisation |
KR20210019422A (ko) * | 2018-04-30 | 2021-02-22 | 카토스 테라퓨틱스, 인크. | 암 치료 방법 |
EP3801476A4 (fr) * | 2018-05-25 | 2022-07-06 | Kartos Therapeutics, Inc. | Méthodes de traitement des néoplasmes myéloprolifératifs |
KR20210052497A (ko) * | 2018-08-31 | 2021-05-10 | 암젠 인크 | Mdm2 억제제의 제조 방법 |
CN110963958A (zh) * | 2018-09-30 | 2020-04-07 | 上海长森药业有限公司 | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
WO2021236474A1 (fr) * | 2020-05-22 | 2021-11-25 | Merck Sharp & Dohme Corp. | Nouveaux procédés de préparation de conjugués de la protéine il-2 |
JP2023539867A (ja) | 2020-08-27 | 2023-09-20 | 大塚製薬株式会社 | Mdm2アンタゴニストを用いた癌治療に関するバイオマーカー |
GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
WO2023014160A1 (fr) * | 2021-08-05 | 2023-02-09 | (주)바이오팜솔루션즈 | Forme cristalline de phénylcarbamate et son procédé de préparation |
US12054449B2 (en) | 2021-08-05 | 2024-08-06 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate crystalline form and method for manufacturing the same |
WO2023039161A1 (fr) * | 2021-09-09 | 2023-03-16 | Kartos Therapeutics | Procédés de traitement du cancer dépendant de l'expression du gène myc |
WO2023056069A1 (fr) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2483213A (en) * | 1947-06-14 | 1949-09-27 | American Cyanamid Co | Alpha naphthalene sulfonic anhydride |
GB1016828A (en) | 1961-11-13 | 1966-01-12 | Mcneilab Inc | Substituted morpholines and process for preparing same |
US3518236A (en) * | 1967-07-20 | 1970-06-30 | Uniroyal Inc | Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives |
DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
JP2604472B2 (ja) | 1989-07-12 | 1997-04-30 | 株式会社クラレ | 重合性組成物 |
US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
WO1995023135A1 (fr) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Derives de diphenyl-2-piperidinone et -2-pyrrolidinone possedant une activite anticonvulsivante et neuroprotectrice |
EP1186603A3 (fr) | 1994-08-19 | 2003-07-09 | Abbott Laboratories | Procédés de préparation d'antagonistes de l'endotheline |
WO1997030045A1 (fr) | 1996-02-13 | 1997-08-21 | Abbott Laboratories | Derives de pyrrolidine a substitution benzo-1,3-dioxolyl et benzofuranyl servant d'antagonistes de l'endotheline |
US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
SK1452000A3 (en) | 1997-08-04 | 2001-05-10 | Abbott Lab | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
WO1999031507A1 (fr) | 1997-12-18 | 1999-06-24 | Eli Lilly And Company | Banques combinatoires sur la base de matrices peptidomimetiques |
US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
US7214540B2 (en) * | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US6630006B2 (en) * | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
US7052545B2 (en) * | 2001-04-06 | 2006-05-30 | California Institute Of Technology | High throughput screening of crystallization of materials |
US7195670B2 (en) * | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
DE19951418A1 (de) * | 1999-10-26 | 2001-05-03 | Merck Patent Gmbh | Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid |
WO2002017912A1 (fr) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Antagonistes de l'endotheline |
WO2002042731A2 (fr) * | 2000-11-20 | 2002-05-30 | Parallel Synthesis Technologies, Inc. | Procedes et dispositifs pour une cristallisation a haut debit |
HUP0304058A2 (hu) | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
EP1408986B1 (fr) | 2001-05-08 | 2008-09-24 | Yale University | Composes proteomimetiques et procedes correspondants |
EP1395560A1 (fr) | 2001-05-23 | 2004-03-10 | Ucb, S.A. | Derives d'acide alcanoique 2-oxo-piperidinyl- et 2-oxo-azepanyle destines au traitement de l'epilepsie et d'autres troubles neurologiques |
AU2002366278B2 (en) | 2001-12-18 | 2007-07-19 | F. Hoffmann-La Roche Ag | CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
US6860940B2 (en) * | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
KR20110033964A (ko) | 2004-05-18 | 2011-04-01 | 에프. 호프만-라 로슈 아게 | 신규 cis-이미다졸린 |
US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
JP2007297283A (ja) * | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
EA012181B1 (ru) | 2004-10-18 | 2009-08-28 | Амген, Инк. | Соединения тиадиазола и их применение |
MX2007010054A (es) | 2005-02-18 | 2007-09-21 | Mitsubishi Pharma Corp | Sal de un derivado de prolina, solvato de la misma y metodo de produccion de la misma. |
KR20100031783A (ko) | 2005-03-16 | 2010-03-24 | 에프. 호프만-라 로슈 아게 | 시스-2,4,5-트리아릴-이미다졸린 및 항암 약제로서의 그의 용도 |
US20090131480A1 (en) | 2005-04-04 | 2009-05-21 | Eisai Co., Ltd. | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia |
EP1888120B1 (fr) * | 2005-06-07 | 2012-12-05 | Ramot at Tel Aviv University Ltd. | Nouveaux sels de medicaments psychotropes conjugues et leurs procedes de preparation |
WO2007015929A2 (fr) * | 2005-07-27 | 2007-02-08 | University Of Toledo | Analogues d'epothilone |
RU2442779C2 (ru) | 2005-12-01 | 2012-02-20 | Ф. Хоффманн-Ля Рош Аг | Производные 2,4,5-трифенилимидазолина как ингибиторы взаимодействия между белками p53 и mdm2, предназначенные для применения в качестве противораковых средств |
EP1981884B1 (fr) | 2006-01-18 | 2012-06-13 | Amgen, Inc | Composés thiazoliques comme inhibiteurs de protéine kinase b |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
MX2009000285A (es) | 2006-06-30 | 2009-06-08 | Schering Corp | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. |
CA2657034A1 (fr) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Dicetoacides de pyridinone : inhibiteurs de la replication du vih dans une therapie combinee |
WO2008021339A2 (fr) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine et dérivés associés utiles en tant que modulateurs des récepteurs de la progestérone |
US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
JP2010522177A (ja) | 2007-03-23 | 2010-07-01 | アムジエン・インコーポレーテツド | 複素環化合物およびその使用 |
EA017389B1 (ru) | 2007-03-23 | 2012-12-28 | Амген Инк. | Гетероциклические соединения и их применение |
PT2139882E (pt) | 2007-03-23 | 2014-01-30 | Amgen Inc | Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k) |
US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
WO2008130614A2 (fr) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Antagonistes p53/mdm2/mdm4 sélectifs et à action double |
US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
WO2009004430A1 (fr) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate |
AU2008273891B2 (en) | 2007-07-09 | 2012-01-12 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
EP2173728A2 (fr) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Modulateurs hétérocycliques de pkb |
CA2693473A1 (fr) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazoles modulateurs de l'activite de pkb |
ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
WO2009047161A1 (fr) | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Cis-imidazolines chirales |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
JP5520831B2 (ja) | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
JP2011507799A (ja) | 2007-12-26 | 2011-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癲癇のためのampa受容体アンタゴニストおよびゾニサミド |
WO2009114950A1 (fr) | 2008-03-21 | 2009-09-24 | Chlorion Pharma, Inc. | Composés de pyrrolidine et de pipéridine substitués, leurs dérivés et procédés de traitement de la douleur |
ES2474147T3 (es) | 2008-05-30 | 2014-07-08 | Amgen, Inc | Inhibidores de PI3 cinasa |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
WO2010030704A2 (fr) * | 2008-09-10 | 2010-03-18 | Achaogen, Inc. | Analogues d’aminoglycosides antibactériens |
TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
CN102159207B (zh) | 2008-09-18 | 2015-02-04 | 霍夫曼-拉罗奇有限公司 | 取代的吡咯烷-2-甲酰胺类 |
US20110263647A1 (en) | 2009-01-15 | 2011-10-27 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
EP2398791A1 (fr) | 2009-02-18 | 2011-12-28 | Amgen, Inc | Composés d'indole ou benzimidazole convenant comme inhibiteurs de la kinase mtor |
CA2755285C (fr) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibiteurs de pi3 kinase |
US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
AU2010249040B2 (en) | 2009-05-13 | 2013-08-22 | Amgen Inc. | Heteroaryl compounds as PIKK inhibitors |
AU2010265932B2 (en) | 2009-06-25 | 2014-11-20 | Amgen Inc. | Heterocyclic compounds and their uses |
CA2765819A1 (fr) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Composes heterocycliques et leurs utilisations en tant qu'inhibiteurs de l'activite p13 k |
US8754089B2 (en) | 2009-06-25 | 2014-06-17 | Amgen Inc. | Heterocyclic compounds and their uses |
AR077267A1 (es) | 2009-06-25 | 2011-08-17 | Amgen Inc | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. |
IN2012DN01693A (fr) | 2009-08-26 | 2015-06-05 | Novartis Ag | |
EP2486044A2 (fr) * | 2009-10-09 | 2012-08-15 | Achaogen, Inc. | Analogues d'aminoglycoside antibactériens |
US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
TW201137923A (en) * | 2010-02-10 | 2011-11-01 | Halcyon Molecular Inc | Aberration-correcting dark-field electron microscopy |
IT1399923B1 (it) * | 2010-05-11 | 2013-05-09 | Cbb Net S A | Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
KR101875720B1 (ko) * | 2011-01-10 | 2018-07-09 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
TW201311938A (zh) * | 2011-04-28 | 2013-03-16 | Otsuka Chemical Co Ltd | 偶氮二甲醯胺之新穎製造法 |
TW201309651A (zh) * | 2011-06-29 | 2013-03-01 | Otsuka Pharma Co Ltd | 阿立哌唑(aripiprazole)無水物B形結晶微粒子之製造方法 |
WO2013049250A1 (fr) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer |
CN103373951B (zh) * | 2012-04-28 | 2016-03-09 | 上海医药工业研究院 | 一种拉帕替尼中间体的制备方法 |
MX362896B (es) | 2013-02-19 | 2019-02-22 | Amgen Inc | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. |
AU2014223547B2 (en) | 2013-02-28 | 2017-11-16 | Amgen Inc. | A benzoic acid derivative MDM2 inhibitor for the treatment of cancer |
WO2014151863A1 (fr) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Composés morpholinone d'acide hétéroaryle utilisés comme inhibiteurs de mdm2 pour le traitement du cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
-
2013
- 2013-06-10 JO JOP/2020/0296A patent/JOP20200296A1/ar unknown
-
2014
- 2014-06-09 PE PE2015002561A patent/PE20160113A1/es unknown
- 2014-06-09 CN CN201910783352.1A patent/CN110627708A/zh active Pending
- 2014-06-09 AU AU2014278428A patent/AU2014278428B2/en active Active
- 2014-06-09 CA CA3201958A patent/CA3201958A1/fr active Pending
- 2014-06-09 PL PL14735785T patent/PL3008039T3/pl unknown
- 2014-06-09 MY MYPI2015002896A patent/MY194848A/en unknown
- 2014-06-09 PT PT147357859T patent/PT3008039T/pt unknown
- 2014-06-09 DK DK14735785.9T patent/DK3008039T3/da active
- 2014-06-09 MA MA53572A patent/MA53572A1/fr unknown
- 2014-06-09 HU HUE14735785A patent/HUE053047T2/hu unknown
- 2014-06-09 CA CA2914723A patent/CA2914723C/fr active Active
- 2014-06-09 JP JP2016519576A patent/JP6998655B2/ja active Active
- 2014-06-09 CN CN201811222652.4A patent/CN110003092A/zh active Pending
- 2014-06-09 EP EP14735785.9A patent/EP3008039B1/fr active Active
- 2014-06-09 EP EP20197741.0A patent/EP3805232A1/fr active Pending
- 2014-06-09 CA CA3115609A patent/CA3115609C/fr active Active
- 2014-06-09 RS RS20201515A patent/RS61192B1/sr unknown
- 2014-06-09 EA EA201891642A patent/EA201891642A1/ru unknown
- 2014-06-09 BR BR122020003153-0A patent/BR122020003153B1/pt active IP Right Grant
- 2014-06-09 CN CN201480033215.1A patent/CN105358530A/zh active Pending
- 2014-06-09 NZ NZ714821A patent/NZ714821A/en unknown
- 2014-06-09 KR KR1020217030265A patent/KR20210121270A/ko not_active Application Discontinuation
- 2014-06-09 EA EA202091612A patent/EA202091612A1/ru unknown
- 2014-06-09 LT LTEP14735785.9T patent/LT3008039T/lt unknown
- 2014-06-09 UA UAA201600159A patent/UA121301C2/uk unknown
- 2014-06-09 SI SI201431735T patent/SI3008039T1/sl unknown
- 2014-06-09 KR KR1020237002549A patent/KR20230019216A/ko not_active Application Discontinuation
- 2014-06-09 ES ES14735785T patent/ES2851023T3/es active Active
- 2014-06-09 MX MX2015016856A patent/MX2015016856A/es unknown
- 2014-06-09 TN TN2015000521A patent/TN2015000521A1/en unknown
- 2014-06-09 EA EA201592305A patent/EA031254B1/ru unknown
- 2014-06-09 SG SG10201801402XA patent/SG10201801402XA/en unknown
- 2014-06-09 KR KR1020157036194A patent/KR20160018576A/ko not_active Application Discontinuation
- 2014-06-09 PE PE2020000392A patent/PE20210153A1/es unknown
- 2014-06-09 AP AP2015008891A patent/AP2015008891A0/xx unknown
- 2014-06-09 SG SG11201509896VA patent/SG11201509896VA/en unknown
- 2014-06-09 CR CR20210290A patent/CR20210290A/es unknown
- 2014-06-09 BR BR112015031004-4A patent/BR112015031004B1/pt active IP Right Grant
- 2014-06-09 WO PCT/US2014/041594 patent/WO2014200937A1/fr active Application Filing
- 2014-06-09 IL IL297860A patent/IL297860A/en unknown
- 2014-06-09 MA MA38714A patent/MA38714A1/fr unknown
- 2014-06-09 CA CA3200532A patent/CA3200532A1/fr active Pending
- 2014-06-10 TW TW107134691A patent/TWI698428B/zh active
- 2014-06-10 JO JOP/2014/0186A patent/JO3768B1/ar active
- 2014-06-10 AR ARP140102235A patent/AR096582A1/es not_active Application Discontinuation
- 2014-06-10 TW TW103120104A patent/TWI649306B/zh active
- 2014-06-10 UY UY0001035605A patent/UY35605A/es not_active Application Discontinuation
- 2014-06-10 TW TW109118829A patent/TWI791153B/zh active
- 2014-06-10 US US14/301,087 patent/US9376386B2/en active Active
-
2015
- 2015-11-16 IL IL242622A patent/IL242622B/en active IP Right Grant
- 2015-12-03 PH PH12015502705A patent/PH12015502705A1/en unknown
- 2015-12-08 MX MX2019012007A patent/MX2019012007A/es unknown
- 2015-12-10 CL CL2015003589A patent/CL2015003589A1/es unknown
- 2015-12-23 MA MA43288A patent/MA43288B1/fr unknown
-
2016
- 2016-01-07 CR CR20160010A patent/CR20160010A/es unknown
- 2016-05-24 US US15/163,186 patent/US9855259B2/en active Active
- 2016-06-07 US US15/175,821 patent/US9757367B2/en active Active
- 2016-06-07 US US15/175,824 patent/US9801867B2/en active Active
- 2016-06-07 US US15/175,805 patent/US9623018B2/en active Active
- 2016-06-07 US US15/175,798 patent/US20160287570A1/en not_active Abandoned
-
2017
- 2017-11-22 US US15/820,830 patent/US20180092898A1/en not_active Abandoned
-
2018
- 2018-11-07 AU AU2018260844A patent/AU2018260844B2/en active Active
-
2019
- 2019-01-08 CL CL2019000056A patent/CL2019000056A1/es unknown
- 2019-05-07 IL IL266504A patent/IL266504B/en active IP Right Grant
- 2019-10-25 US US16/664,103 patent/US20200281912A1/en not_active Abandoned
-
2020
- 2020-04-28 AR ARP200101191A patent/AR119727A2/es unknown
- 2020-05-14 JP JP2020084989A patent/JP6891322B2/ja active Active
- 2020-11-10 AU AU2020267169A patent/AU2020267169B2/en active Active
- 2020-12-18 CY CY20201101201T patent/CY1123661T1/el unknown
- 2020-12-24 HR HRP20202065TT patent/HRP20202065T1/hr unknown
-
2021
- 2021-03-08 CL CL2021000566A patent/CL2021000566A1/es unknown
- 2021-03-25 IL IL281807A patent/IL281807B2/en unknown
- 2021-05-25 JP JP2021087378A patent/JP7263439B2/ja active Active
- 2021-10-13 US US17/500,039 patent/US20220280496A1/en not_active Abandoned
-
2022
- 2022-11-16 AU AU2022271425A patent/AU2022271425B2/en active Active
-
2023
- 2023-04-12 JP JP2023064715A patent/JP2023089126A/ja active Pending
- 2023-05-08 US US18/313,428 patent/US20230301974A1/en active Pending
-
2024
- 2024-09-02 AU AU2024216533A patent/AU2024216533A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43288A1 (fr) | Procédés de production et formes cristallines d'un inhibiteur mdm2 | |
RS54030B1 (en) | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT | |
MA41607A (fr) | Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels | |
WO2014028597A3 (fr) | Composés indazole et indole à substitution cyclohexyl et 3-cyclohexenyl | |
CR20110257A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
TW200736247A (en) | Compounds for the treatment of inflammatory disorders | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
EA201300604A1 (ru) | Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций | |
MA35016B1 (fr) | Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt | |
MA37650A1 (fr) | Forme amorphe d'un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci | |
UA110802C2 (uk) | Моногідрат похідного азаадамантану | |
EA201071367A1 (ru) | Соли соединений ингибиторов вич | |
EA201390336A1 (ru) | Способ получения промежуточного соединения для синтеза лекарственного средства | |
EA201170736A1 (ru) | Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина | |
EA201170481A1 (ru) | Сокристаллы | |
EP4282973A3 (fr) | Procédés de préparation pour dérivés de pyrmidinecyclopentane | |
IN2013MU00916A (fr) | ||
EA202190632A1 (ru) | Способы получения ингибитора mdm2 | |
MX361764B (es) | Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas. | |
MX2014002343A (es) | Inhibidores de parp. | |
IN2013MU02719A (fr) | ||
IN2013MU02793A (fr) |